Our clients operate in dual environments—life science and business—and we shape our teams around the common challenges facing these segments. Valid Insight experts draw on decades of market access, medical and relevant commercial experience.
BSc (Hons.), MB BChir, MRCOphth
Steve Bradshaw is Managing Director of Valid Insight. He has two decades’ experience in market access consulting and healthcare. He has developed price and access strategies and value communication tools for many well-known products on the market, and has supported numerous companies on many aspects of market access, pricing, tendering, contracting, value communication and operational excellence.
Steve’s career includes being Editor at Nature Clinical Reviews, Ophthalmic Surgeon UK National Health Service, and various positions to senior executive level in market access consulting firms including United BioSource Corporation, Evidera and Market Access Solutions LLC, prior to launching Valid Insight. His education includes a first-class BSc in Biochemistry, degrees in Medicine and Surgery from Gonville and Caius College, Cambridge, and a postgraduate diploma in Ophthalmology.
Steve writes and speaks regularly on the challenges facing the global healthcare environment; he presents widely at conferences and expert panels, and has authored over 30 publications. His research interests span multiple therapy areas across drugs, devices and biotechnologies, including innovative medicines for rare diseases. He is a peer reviewer for several medical journals, Editorial Board Member for the journal Medicine Access @ Point of Care, Advisory Board Member at Pharma-IQ and the Global Pneumonia Prevention Coalition, and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, and Reuters.
Raf De Wilde
Senior Executive Advisor
Raf De Wilde is Senior Executive Advisor at Valid Insight. He is a global expert in life science market access, having over 37 years’ experience in the pharmaceutical industry and over 27 years in global market access.
Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.
In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010.
Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015, prior to joining Valid Insight in 2016. In his consulting career he has led over 100 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 120 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.
Raf continues to teach the sessions on PROs and evidence-based medicine at the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.
Frank Cousins is Senior Director at Valid Insight. He has over 20 years’ experience as a consultant to the pharmaceutical industry, having recently joined after 10 years at IQVIA (Quintiles Consulting). Frank’s career includes over 10 years in healthcare and medical communications, both educational and commercial, before joining Quintiles Consulting where from 2008-2018 he worked in a range of senior positions to Principal level. His experience is end-to-end from evidence generation and clinical trial optimisation projects through to launch and eventual loss of exclusivity, across many therapeutic categories, particularly oncology, haematology, immunology, and mental health.
His consulting experience has focussed on delivering diverse and complex multifaceted programs that have included organisational design, alliance and partnership evaluation, market evaluation, payer and pricing strategies and eHealth initiatives. Most recently Frank has focussed on the integration of regulatory strategy, evidence generation (including clinical studies, real world evidence, and patient centric and PRO data), and market access for optimal launch and commercial planning. He has developed a high level of expertise in early regulatory approval and its implications for evidence generation, HTA, and market access, pricing and reimbursement.
Frank has a BSc (Hons.) in Biology from St Andrews University.
BA, MA, MSc, DPhil
Crispin Jenkinson is Senior Advisor at Valid Insight. He is Professor of Health Services Research, Director of the Health Services Research Unit at the Nuffield Department of Population Health, and a Senior Research Fellow of Harris Manchester College at the University of Oxford. He graduated from Bedford College (University of London) before coming to Oxford where he gained an MSc in Psychology and then undertook research on the psychological impact of long-term illness for a DPhil. His main research interests include patient reported outcomes (PROs) and health status measurement, the evaluation of patient experiences of medical care, and methodology. He has extensive experience of developing and validating outcome measures and, in collaboration with others, has conducted randomised controlled trials in which such instruments have been primary end-points. This work has led to the development of several internationally recognized PRO measures including the Parkinson’s Disease Questionnaire (PDQ), Amyotrophic Lateral Sclerosis Questionnaire (ALSAQ), and the Endometriosis Health Profile (EHP). He has written and edited many books as well as having authored over 210 peer reviewed publications.
Crispin helps our clients develop fit-for-purpose PRO and other health status instruments.
Carole Alison Chrvala
Carole Chrvala is Senior Advisor at Valid Insight. She has over 25 years’ experience as an epidemiologist and HEOR researcher. Her work spans collaborations with government health agencies, payers, academic institutions, pharmaceutical and medical device companies, medical education and communication organisations, and healthcare professional societies located in the US, UK, EU, and Israel. Carole is highly experienced in epidemiologic consulting, biostatistical support, strategic competitive analysis, medical intelligence, medical writing and publication planning services in diverse therapeutic areas including oncology, cardiovascular disease, diabetes mellitus, infectious diseases, musculoskeletal disorders, neurologic disorders, pain, psychiatric disorders, rare diseases, respiratory disorders, rheumatologic disorders, and women’s health.
Carole has developed and validated risk prediction models for various chronic and infectious diseases, analysed health care resource utilisation and economic burden, determined projections for the global epidemiologic burden of diverse health conditions, developed prospective and retrospective research studies to examine the impact of clinical interventions and developed statistical analysis plans for retrospective and prospective case-control studies and randomised clinical trials.
Carole was director of Cancer Prevention and Control for the Colorado Department of Public Health and Environment (CDPHE), before setting up her own independent company. She joined the US Food and Drug Administration as a Senior Scientist and later joined the National Academies of Science as a Senior Program Officer. She has written and presented on epidemiology, health economics and outcomes research, and diverse health topics to more than 75 professional audiences and organisations.
Alia Karaouni is Senior Advisor at Valid Insight. She is an experienced strategy consultant and foresight expert. Alia has a proven track record in decision support for senior pricing and market access management in the pharmaceutical industry. Her in-depth knowledge of biotech and pharma stems from 15 years of consultancy work, as well as work in the industry, on issues related to pricing strategy, market access, portfolio analysis, cost-benefit assessment, commercial planning and valuation, among others.
Alia has over 20 years’ experience helping clients tackle complex management decision-making in highly-uncertain, rapidly-changing environments, through issue framing, discussion facilitation and simulation-tool building. Alia was head of market access for three years ad interim at Onxeo, a Paris-based small biotech company with several orphan oncology drugs in development. Prior to this, she worked for the World Economic Forum in Geneva, as deputy head of scenario planning. Here she directed several year-long scenario projects exploring the future of industries and regions, with the outcomes made public at the annual Davos meeting. She has also worked as a management consultant in Brussels for IBM Business Consulting Services and PricewaterhouseCoopers, before setting up her own independent company, using her expertise in the field of systems thinking and business modelling to support business strategy and decision-making
Alia holds a PhD in Economics from MIT, a Master’s degree in Econometrics and a Bachelor’s degree in Economics from Université de Montréal.
Dip HE, MSc
James Wright is Associate Director at Valid Insight and has over twenty years’ experience in the healthcare industry and consulting. He joined Valid Insight after 13 years at QuintilesIMS.
James has provided market access support to most of the top 25 pharmaceutical companies and has extensive experience in HTA optimisation, evaluation of strategic pricing and market access implications for new launches, and product/portfolio lifecycle optimisation. James’ experience covers all major therapy areas, including rare and orphan disease, plus extensive work in biologics across established and emerging markets. James also specialises in clinical trial assessment, payer positioning, value and pricing strategy and lifecycle management.
James has an MSc in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra.
BSc (Hons), PGCert Health Economics
Associate Director – Value Comms
Carolyn has 30 years’ experience in the healthcare industry, comprising 15 years in pharmaceuticals, 12 years in consultancy and 3 years in diagnostics. Over 20 years of this time has been spent working in HEOR and Market Access where Carolyn gained considerable experience in developing: value dossiers and key value messages, market access strategies, value communication tools, health economic data to support pricing and reimbursement and outcomes research studies.
Carolyn worked for many years in consultancy as an independent consultant in the area of HEOR and value communications, and for several years in market access consultancy. Carolyn has managed numerous projects working with large global pharmaceutical companies to smaller diagnostic manufacturers delivering high quality deliverables across a wide range of therapy areas including; oncology, infectious diseases, neurology, ophthalmology, medical devices (insulin pumps, gastric bands) and in-vitro Diagnostics (biomarker testing for cancer, molecular assays for infection).
Most recently Carolyn was responsible for developing value messages, with supporting clinical and economic evidence, and the appropriate value communication tools to support adoption of new assays for the diagnosis of infectious diseases.
Carolyn has an honours degree in Biology from Strathclyde University and a postgraduate certificate in Health Economics from Aberdeen University.
Federica Benassi is a Consultant at Valid Insight. She began her career as a Policy Officer at HOSPEEM in Belgium, an organisation that represents national hospital and healthcare sector employers’ associations at the European level, where she worked on projects financed by the European Commission. She then gained deep experience in European healthcare policy, pricing and reimbursement in consulting roles at IHS Markit, QuintilesIMS then IQVIA, prior to joining Valid Insight.
Federica has worked with many clients managing the execution of market access projects from proposal through to delivery, on numerous therapy areas including oncology, haematology, ophthalmology, cardiovascular and CNS. Federica has worked on many pharmaceuticals, devices and advanced therapy medicinal products. She specialises in healthcare policy, pharmaceutical pricing and market access strategy.
Federica has a MSc in Health Policy, Planning and Financing from the London School of Economics and Political Science and the London School of Hygiene and Tropical Medicine, and she has an MA in Organisation and Governance from the University of Bologna. Federica is bilingual in Italian and English.
Ellen Murphy is a Consultant at Valid Insight with over five years consulting experience in the pharmaceutical and medical device industry. She started her career at Parexel and thereafter worked at Cogora prior to joining Valid Insight in 2018.
She has experience from global projects with a focus on the EU5 and has worked on a range of therapy areas. Her project experience includes a variety of market access projects ranging from evidence generation projects such as systematic reviews and HTA, to pricing and strategy projects, all the way to development of data tools to be used by pharma clients in discussions with payers or by their in-house team. She also has experience producing objections handlers and providing training to client salesforce teams.
Ellen has a BSc (Hons) in Psychology from St Andrews University and a PhD in Neuroscience from Cardiff University.
Please use the contact form if you have any questions about our services.
152 City Road
+44 (0) 20 3750 9833